Replacing the PKP2 gene prolongs survival in ARVC patients 31 January 2024 | By Drug Target Review The new study suggests that this gene therapy method may combat ARVC in both early and more advanced stages of the condition.
Augmenting cancer immunogenicity through MHC class I 31 January 2024 | By Drug Target Review A novel technology can reduce tumour sizes significantly and improve treatment efficacy when used with existing immunotherapy.
Targeting GBA gene variants for treating Parkinson’s disease 30 January 2024 | By Drug Target Review A new project plans to elucidate the relationship between the glucosylceramidase beta gene and Parkinson’s disease.
Improving cancer treatment by exploiting mtDNA mutations 30 January 2024 | By Drug Target Review For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
Novel prediction tool accurately determines disease stage 29 January 2024 | By Drug Target Review A new learning-based framework enables patients and caregivers to predict the timing of any of the five clinical groups of AD development.
Targeting Ku70 could improve bowel cancer treatment 29 January 2024 | By Drug Target Review The Ku70 protein prevents cancer cells from becoming more aggressive and metastasising. It could also be used as an immune biomarker.
X-ray irradiation reversed motor deficits after brain injury 26 January 2024 | By Drug Target Review Low dose ionising radiation reduced lesion size and reversed motor deficits in traumatic brain injury and ischemic stroke mice.
CRISPR activation: quicker diagnosis of rare genetic diseases 26 January 2024 | By Drug Target Review Using CRISPRa to activate genes in readily accessible cells provides an effective and accurate diagnosis of genetic diseases.
How the HIV capsid has evolved into a molecular transporter 25 January 2024 | By Drug Target Review The discovery that HIV capsids are importin-like transporters could be exploited for improved AIDS therapies.
New immunological pathway to treat bone tumours 25 January 2024 | By Drug Target Review Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
The potential of PD-L2 inhibitors for cancer treatment 24 January 2024 | By Drug Target Review Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
PLK4 inhibition: a new therapeutic for AML 24 January 2024 | By Drug Target Review PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
Advancing personalised medicine with a cholangiocarcinoma model 23 January 2024 | By Drug Target Review A patient-specific organ-on-a-chip model of cholangiocarcinoma, with its tumour microenvironment, helps to predict therapy response.
How PD-1 promotes Merkel cell carcinoma progression 23 January 2024 | By Drug Target Review Inhibiting mTOR signalling and neutralising mtROS suppressed MCC-PD-1-mediated tumour proliferation in mice.
Off-switches developed for CRISPR-Cas3 technologies 22 January 2024 | By Drug Target Review AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
